Jin Q, Harris E, Myers JA, Mehmood R, et al. Disruption of cotranscriptional splicing suggests that RBM39 is a therapeutic target in acute lymphoblastic leukemia. Blood 2024 Sep 24:blood.2024024281. doi: 10.1182/blood.2024024281.
PMID: 39316649